AlphAIAlphAI — Financial news for AI agents
investing.com$EVH

Evolent Health stock falls 7% on revenue miss despite in-line earnings

Evolent Health Inc. (EVH) reported Q3 revenue of $725.37M, missing estimates, while earnings matched expectations. Shares fell 7.29% premarket. The company maintained 2026 revenue guidance and raised adjusted EBITDA guidance. Net loss narrowed YoY, but adjusted EBITDA margin declined.

Original reporting
investing.com
Published Nov 5, 2026, 12:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 12:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$EVH
Bearish
medium confidence
Mentioned
$EVH
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$EVHBearishHigh
01

Why it matters

The miss triggered a 7% pre‑market decline, suggesting short‑term downside risk.

02

Market read

Evolent's earnings miss provides a fresh trading signal for the stock and may influence peer valuations.

03

What to watch

Raised EBITDA guidance and renewed contracts could offset the revenue shortfall.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Evolent Health reported Q3 results with revenue slightly below consensus but maintained full‑year guidance.

Company-level read

Ticker impact

$EVHBearishMedium confidence
Context

Shares fell 7.3% pre‑market after Q3 revenue missed estimates and earnings were in‑line.

Expected impact

likely pressure as the market prices in the revenue shortfall.

Evidence & confidence

The miss was modest in absolute dollars but caused a sharp pre‑market drop, indicating sensitivity to top‑line guidance.

Market effects

Sector

May weigh on other health‑tech firms with similar revenue models.

Regional

Limited to U.S. healthcare services sector.

Global

Low, as the company is U.S.-focused.

Counterpoint

What could challenge this read

The revenue miss is small relative to growth; the stock could rebound on strong guidance range.

Key entities

  • company
    Evolent Health Inc.

    U.S. healthcare solutions provider.

Read at source← All news

StoryEvolent Health posts Q3 2026 loss, lifts full‑year Adjusted EBITDA guidance

Also covered by

4 outlets

Related articles

$EVHMedAI 8/10

EVH Q3 2026 deep dive: ongoing AI investment and customer expansion shape outlook

EVH reported Q3 2026 revenue of $725.4M (51.3% YoY growth, in line with estimates) and adjusted EPS of $0.06 (in line). Adjusted EBITDA was $34.26M, beating estimates by 3.1%. The company reconfirmed full-year revenue guidance of $2.65B and raised EBITDA guidance to $132.5M. Sales volumes fell 4.2% YoY, while operating margin declined to -0.9%. EVH expanded its AI platform, Oncology care, and National payer scale, citing cost savings and margin expansion potential.

finance.yahoo.com
$EVHMed

Evolent Health, Inc. Q3 2026 Earnings Call Summary

Evolent Health reported 11% sequential revenue growth driven by Highmark Performance Suite and contractual adjustments. MER improved to 93%. Management prioritizes margin expansion and cash generation, with oncology expected to represent over 70% of revenue by 2027. AI platform scales, processing 1M cases annually. Management reiterated 2027 Adjusted EBITDA confidence of $150M+ and plans $50M debt reduction by 2026 year-end.

finance.yahoo.com
$EVHMedAI 8/10

Evolent Health (EVH) Q3 2026 Earnings Call Transcript

Evolent Health (EVH) reiterated its full-year revenue guidance of $2.6B-$2.7B and raised Adjusted EBITDA guidance to $130M-$135M. The company reported customer contract renewals and expansions, including a 4-year renewal with its largest Surgical Management customer and expansions in oncology and specialty services.

finance.yahoo.com
$EVHMed

Evolent Health: Q3 Earnings Snapshot

Evolent Health (EVH) reported a Q3 loss of $23.6M, or 21 cents per share, with adjusted earnings of 6 cents per share, meeting expectations. Revenue was $725.4M, below the $734.3M forecast. The company expects full-year revenue between $2.6B and $2.7B.

finance.yahoo.com
$EVHMed

Evolent Announces Third Quarter 2026 Results

Evolent Health, Inc. (EVH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Evolent Announces Third Quarter 2026 Results WASHINGTON (November 5, 2026) – Evolent Health, Inc. (NYSE: EVH) (“Evolent” or the “Company”), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make heal

SEC EDGAR 8-K